1. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
2. Diehm C, Lange S, Darius H et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27 (14): 1743–9.
3. Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается. Тер. арх. 2006; 9: 5–12.
4. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18: 3S–10S
5. Мухин Н.А. Снижение скорости клубочковой фильтрации – общепопуляционный маркер неблагоприятного прогноза. Тер. арх. 2007; 6: 5–10.
6. Земченков А.Ю., Томилина Н.А. «К/ДОКИ» обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек). Нефрол. и диализ 2004; 6(3): 204–20.
7. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331–40.
8. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; 13 (5): 1338–49.
9. Redon J, Cea-Calvo L, Lozano JV et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens 2006; 24 (4): 663–9.
10. Bibbins-Domingo K, Chertow GM, Fried LF et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166 (13): 1396–402.
11. Lindholm L, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.
12. Brown B, Hall A. Renin-angiotensin system: the weight of evidence. Am J Hypertens 2005; 18: 127S–133S.
13. Brenner B, Cooper M, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861–9.
14. Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851–60.
15. Schupp M, Pharm B, Janke J et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-γ activity. Circulation 2004; 109: 2054–7.
16. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7 (2): 140–5.
17. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сonsilium Medicum 2006; 8 (11): 25–30.
18. Kintscher U, Bramlage P, Paar WD et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol 2007; 6: 12–7.
19. Ram CV. Angiotensin blockade with eprosartan: vascular and functional implications. Curr Med Res Opin 2007; 23 (Suppl. 5): S5–S11.
20. Balt JC, Mathy MJ, Nap A et al. Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery. J Cardiovasc Pharmacol 2002; 40 (1): 50–7.
21. Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RRJr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55 (5): 244–51.
22. Vase H, Lauridsen TG, Bech JN et al. Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans. Br J Clin Pharmacol 2008; 65 (6): 822–32.
23. Jooles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699–706.
24. Rump LC, Amann K, Orth S, Ritz E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uremia. Nephrol Dial Transplant 2000; 15: 1735–48.
25. Neumann J, Ligtenberg G, Klein IH et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49 (3): 506–10.
26. Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30 (2 Pt. 1): 240–6.
27. Сагинова Е.А., Федорова Е.А., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. арх. 2005; 5: 36–41.
28. Frank H, Schobel HP, Vitkowsky J et al. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. Kidney Int 2003; 63 (2): 617–23.
29. Ilson BE, Boike SC, Martin DE et al. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men. Clin Pharmacol Ther 1998; 63 (4): 471–81.
30. Моисеев С.В., Фомин В.В. Нефрологические аспекты хронической сердечной недостаточности. Тер. арх. 2003; 6: 72–6.
31. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248–54.
32. Brodsky S, Gurbanov K, Abassi Z et al. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension 1998; 32: 746–52.

В.В.Фомин

Кафедра терапии и профболезней ММА им. И.М.Сеченова